Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Spero Therapeutics, Inc. granted equity awards to a new employee as a material inducement for their employment.
Stocks · News reference
Spero Therapeutics Announces Leadership Appointments and COO Retirement
Spero Therapeutics has appointed Amy Rock as Chief Regulatory and Quality Officer and Dae Gon Ha as Senior Vice President of Corporate Development, while announcing the upcoming retirement of COO Timothy Keutzer.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Spero Therapeutics Announces Participation in Upcoming Investor Conferences
Spero Therapeutics announced that its leadership team will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference and the Jefferies Global Healthcare Conference.
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday
Analysts initiated bullish coverage on Rubrik, Kardigan, MSG Rangers and Ormat Technologies, with price targets of $155, $50, $257 and $123.
Spero Therapeutics Price Target Announced at $6.00/Share by Cantor Fitzgerald
Cantor Fitzgerald has initiated coverage on Spero Therapeutics with a price target of $6.00 per share.
8-K filing — Spero Therapeutics, Inc. (SPRO)
Filed: 2026-10-27 AccNo: 0001193125-26-434452 Size: 137 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Complicated Urinary Tract Infections Market Set for Expansion by 2036, Supported by Recent Drug Approvals Including GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH and Emerging Therapies | DelveInsight
The complicated urinary tract infections (cUTI) market is expected to grow steadily through 2036, driven by rising antimicrobial resistance, increasing recurrent and hospital-acquired infections, and recent drug approvals. Key approvals include GSK/Spero Therapeutics' UTEBZI (oral antibiotic) and Wockhardt's ZAYNICH (intravenous antibiotic), both approved in 2026. Emerging therapies from companies like Venatorx Pharmaceuticals, Meiji Seika Pharma, and Locus Biosciences targeting multidrug-resistant Gram-negative bacteria are expected to further expand the market.